[go: up one dir, main page]

TR200201167T2 - Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri. - Google Patents

Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri.

Info

Publication number
TR200201167T2
TR200201167T2 TR2002/01167T TR200201167T TR200201167T2 TR 200201167 T2 TR200201167 T2 TR 200201167T2 TR 2002/01167 T TR2002/01167 T TR 2002/01167T TR 200201167 T TR200201167 T TR 200201167T TR 200201167 T2 TR200201167 T2 TR 200201167T2
Authority
TR
Turkey
Prior art keywords
sodium
inhibitor crystals
crystals
inhibitor
exchanger type
Prior art date
Application number
TR2002/01167T
Other languages
English (en)
Inventor
Robinson Brostrom Lyle
Joseph Connolly Terrence
Jane Li Zheng
Lee Orrill Susan
Kiritkumar Shah Bharat
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200201167T2 publication Critical patent/TR200201167T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

NHE-1 önleyici kristalleri, bu gibi NHE-1 önleyici kristallerinin kullanim yöntemleri ve bu gibi NHE-1 önleyici kristallerini içeren farmasötik bilesimler. NHE-1 önleyici kristalleri doku isemisi yani dokunun bölgesel olarak kansiz kalmasi sonucu ortaya çikan doku hasarinin azaltilmasi için yararlidirlar.
TR2002/01167T 1999-10-29 2000-10-09 Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri. TR200201167T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
TR200201167T2 true TR200201167T2 (tr) 2002-08-21

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01167T TR200201167T2 (tr) 1999-10-29 2000-10-09 Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri.

Country Status (44)

Country Link
EP (1) EP1224179B1 (tr)
JP (1) JP2003512455A (tr)
KR (1) KR100464526B1 (tr)
CN (2) CN1636991A (tr)
AP (1) AP2002002493A0 (tr)
AR (1) AR029402A1 (tr)
AT (1) ATE271047T1 (tr)
AU (1) AU778573B2 (tr)
BG (1) BG106729A (tr)
BR (1) BR0015275A (tr)
CA (1) CA2389020A1 (tr)
CO (1) CO5271714A1 (tr)
CZ (1) CZ20021332A3 (tr)
DE (1) DE60012208T2 (tr)
DK (1) DK1224179T3 (tr)
DZ (1) DZ3463A1 (tr)
EA (1) EA004937B1 (tr)
EE (1) EE200200227A (tr)
ES (1) ES2222923T3 (tr)
GE (1) GEP20043222B (tr)
GT (1) GT200000180A (tr)
HK (1) HK1048472B (tr)
HR (1) HRP20020366B1 (tr)
HU (1) HUP0204009A3 (tr)
IL (1) IL148581A0 (tr)
IS (1) IS6302A (tr)
MA (1) MA26840A1 (tr)
MX (1) MXPA02004358A (tr)
NO (1) NO20021821D0 (tr)
NZ (1) NZ517738A (tr)
OA (1) OA12080A (tr)
PA (1) PA8505501A1 (tr)
PE (1) PE20010764A1 (tr)
PL (1) PL354869A1 (tr)
PT (1) PT1224179E (tr)
SI (1) SI1224179T1 (tr)
SK (1) SK5312002A3 (tr)
SV (1) SV2002000209A (tr)
TN (1) TNSN00210A1 (tr)
TR (1) TR200201167T2 (tr)
UA (1) UA72002C2 (tr)
WO (1) WO2001030759A2 (tr)
YU (1) YU31502A (tr)
ZA (1) ZA200203295B (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
CZ20032017A3 (cs) * 2001-01-31 2004-05-12 Pfizeráproductsáinc Ethanoláty inhibitoru sodík@vodík měniče typu �Ź způsob jejich přípravyŹ jejich použití a farmaceutický prostředekŹ který je obsahuje
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
BR0309707A (pt) * 2002-05-02 2005-02-09 Pfizer Prod Inc Tratamento de diabetes e complicações diabéticas com inibidores nhe-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
WO2001030759A3 (en) 2001-09-13
CZ20021332A3 (cs) 2002-10-16
ES2222923T3 (es) 2005-02-16
AU778573B2 (en) 2004-12-09
NZ517738A (en) 2005-06-24
ZA200203295B (en) 2003-06-25
IL148581A0 (en) 2002-09-12
JP2003512455A (ja) 2003-04-02
HUP0204009A2 (hu) 2003-03-28
HRP20020366A2 (en) 2004-02-29
ATE271047T1 (de) 2004-07-15
EA200200416A1 (ru) 2002-10-31
KR20020040918A (ko) 2002-05-30
CO5271714A1 (es) 2003-04-30
BG106729A (bg) 2002-12-29
AP2002002493A0 (en) 2002-06-30
CN1384829A (zh) 2002-12-11
SV2002000209A (es) 2002-07-16
DK1224179T3 (da) 2004-10-25
DZ3463A1 (fr) 2001-05-03
NO20021821L (no) 2002-04-18
DE60012208D1 (de) 2004-08-19
PT1224179E (pt) 2004-10-29
EE200200227A (et) 2003-06-16
EP1224179B1 (en) 2004-07-14
HK1048472A1 (en) 2003-04-04
GEP20043222B (en) 2004-04-26
HRP20020366B1 (en) 2005-04-30
OA12080A (en) 2003-08-25
UA72002C2 (en) 2005-01-17
TNSN00210A1 (fr) 2005-11-10
WO2001030759A2 (en) 2001-05-03
BR0015275A (pt) 2002-07-16
PA8505501A1 (es) 2003-09-05
AU7441500A (en) 2001-05-08
CN1205205C (zh) 2005-06-08
SK5312002A3 (en) 2003-01-09
PE20010764A1 (es) 2001-07-23
CN1636991A (zh) 2005-07-13
CA2389020A1 (en) 2001-05-03
DE60012208T2 (de) 2005-07-21
EA004937B1 (ru) 2004-10-28
EP1224179A2 (en) 2002-07-24
GT200000180A (es) 2002-04-11
IS6302A (is) 2002-03-15
YU31502A (sh) 2004-12-31
MXPA02004358A (es) 2002-11-07
HK1048472B (zh) 2005-09-16
HUP0204009A3 (en) 2004-07-28
SI1224179T1 (en) 2004-10-31
MA26840A1 (fr) 2004-12-20
PL354869A1 (en) 2004-03-08
AR029402A1 (es) 2003-06-25
NO20021821D0 (no) 2002-04-18
KR100464526B1 (ko) 2005-01-03

Similar Documents

Publication Publication Date Title
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
DK0931788T3 (da) Metalloproteasehæmmere
TR199901191T2 (tr) Benzamidoaldehitlerin sistein proteazi inhibitörü olarak kullanimi.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
BR9811099A (pt) Inibidores de urocinase
ATE332903T1 (de) Kondensierte pyridoindolderivate
BR0212925A (pt) Derivados de idol como inibidores de cox ii
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
ATE259813T1 (de) Triazolopyrimidinderivate
TR200201167T2 (tr) Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
YU79602A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
TR200100133T2 (tr) FKBP İnhibitörleri
PT1292290E (pt) Composicoes farmaceuticas que compreendem derivados de acriloil-distamicina e inibidores de topoisomerase 1 e ii
BR0107204A (pt) Inibidores da angiogênese de hidrazida e alcoxiamida
BR0016115A (pt) Derivados peptìdicos de acriloìla, processo para sua preparação e seu uso como agentes inibidores de tumor
BR9912374A (pt) Isoquinolinas como inibidores de urocinase